Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BotuGel in Idiopathic OAB
NCT02674269Phase 2Withdrawn
- Sponsor
- UroGen Pharma
- Start
- Oct 2016
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Onabotulinumtoxina + hydrogel in overactive bladder (OAB) (3 arms), sponsored by UroGen Pharma. Primary endpoints: Urinary retention at 6 weeks, Urinary tract infection events at 6 weeks and 2 more. Planned start Oct 2016; status: withdrawn.
02
Drugs
Onabotulinumtoxina + hydrogel
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02674269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02674269.